摘要
目的观察低分子肝素钙、阿司匹林及其联合应用治疗急性脑梗死的疗效及其安全性。方法共选择240例急性脑梗死患者,随机分为低分子肝素钙治疗组、阿司匹林治疗组、低分子肝素钙与阿司匹林联合治疗组及对照组,每组各60例。治疗前后分别作神经功能缺损程度评分及临床疗效判定,并观察每组的不良反应。结果低分子肝素钙治疗组、阿司匹林治疗组、低分子肝素钙与阿司匹林联合治疗组神经功能恢复均明显优于对照组,低分子肝素钙与阿司匹林联合治疗组临床疗效明显优于低分子肝素钙治疗组与阿司匹林治疗组,各组出血发生率无显著差异性。结论脑梗死急性期给予低分子肝素钙联合阿司匹林治疗安全有效,且明显优于单药治疗。
OBJECTIVE: To study the efficacy and safety of low-molecular-weight heparin calcium and aspirin on treating acute cerebral infarction. METHODS: 240 cases with acute cerebral infarction were divided into four groups: the group treated with low-molecular-weight heparin calcium, the group treated with aspirin, the group treated with combined low-molecular-weight heparin calcium and aspirin and control group. The score of neurological defect scores, clinical effect and brain CT changes were observed before and after treatment. RESULTS: The neurological defect scores and clinical effect of cases in three treatment groups were apparently better than those in control group. The neurological defect scores and clinical effects in the group treated with combined low-molecular-weight heparin calcium and aspirin were apparently better than those in the group treated with low-molecular-weight heparin calcium or aspirin. CONCLUSION: The earlier treatment of acute cerebral infarction with low-molecular-weight heparin calcium and aspirin is safe and effective.
出处
《中国药学杂志》
EI
CAS
CSCD
北大核心
2005年第8期634-636,共3页
Chinese Pharmaceutical Journal
关键词
急性脑梗死
阿司匹林
低分子肝素钙
Bioassay
High performance liquid chromatography
Methanol
Optimization
Solvents
Synthesis (chemical)
